For research use only. Not for therapeutic Use.
Mavacoxib is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease. It acts as a COX-2 inhibitor.
| Catalog Number | R015783 |
| CAS Number | 170569-88-7 |
| Synonyms | 4-[5-(4-Fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide; 4-[5-(4-Fluorophenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]benzenesulfonamide; Mavacoxib; PHA 739521; Trocoxil |
| Molecular Formula | C16H11F4N3O2S |
| Purity | ≥95% |
| Target | COX |
| Storage | -20°C |
| IUPAC Name | 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide |
| InChI | InChI=1S/C16H11F4N3O2S/c17-11-3-1-10(2-4-11)14-9-15(16(18,19)20)22-23(14)12-5-7-13(8-6-12)26(21,24)25/h1-9H,(H2,21,24,25) |
| InChIKey | TTZNQDOUNXBMJV-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F)F |
| Reference | </br>1:Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Payne-Johnson M, Becskei C, Chaudhry Y, Stegemann MR.Vet Rec. 2015 Mar 14;176(11):284. doi: 10.1136/vr.102397. Epub 2014 Nov 27. PMID: 25433056 Free PMC Article</br>2:Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, Stegemann M.J Vet Pharmacol Ther. 2015 Feb;38(1):1-14. doi: 10.1111/jvp.12185. Epub 2014 Nov 21. Review. PMID: 25413929 </br>3:The long-acting COX-2 inhibitor mavacoxib (Trocoxil™) has anti-proliferative and pro-apoptotic effects on canine cancer cell lines and cancer stem cells in vitro. Pang LY, Argyle SA, Kamida A, Morrison KO, Argyle DJ.BMC Vet Res. 2014 Sep 5;10:184. doi: 10.1186/s12917-014-0184-9. PMID: 25190452 Free PMC Article</br>4:Mavacoxib and meloxicam for canine osteoarthritis: a randomised clinical comparator trial. Walton MB, Cowderoy EC, Wustefeld-Janssens B, Lascelles BD, Innes JF.Vet Rec. 2014 Sep 20;175(11):280. doi: 10.1136/vr.102435. Epub 2014 May 23. PMID: 24859353 </br>5:Population pharmacokinetics of mavacoxib in osteoarthritic dogs. Cox SR, Liao S, Payne-Johnson M, Zielinski RJ, Stegemann MR.J Vet Pharmacol Ther. 2011 Feb;34(1):1-11. doi: 10.1111/j.1365-2885.2010.01183.x. PMID: 21219337 </br>6:The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs. Cox SR, Lesman SP, Boucher JF, Krautmann MJ, Hummel BD, Savides M, Marsh S, Fielder A, Stegemann MR.J Vet Pharmacol Ther. 2010 Oct;33(5):461-70. doi: 10.1111/j.1365-2885.2010.01165.x. PMID: 20840390 |
